SunRISe-1: Phase 2b study of TAR-200 plus cetrelimab, TAR-200 alone, or cetrelimab alone in participants with high-risk nonmuscle-invasive bladder cancer unresponsive to Bacillus Calmette-Guerin who are ineligible for or decline radical cystectomy.

被引：3
|
作者：
Van der Heijden, Michiel Simon
Cutie, Christopher
Hampras, Shalaka
Indoria, Charu
Stewart, Rachel
Acharya, Milin
Stromberg, Katherine
Li, Xiang
Beeharry, Neil
Maffeo, John
Jacob, Joseph M.
机构：
[1] Netherlands Canc Inst, Amsterdam, Netherlands
[2] Janssen Res & Dev, Clin Oncol, Lexington, MA USA
[3] Janssen Res & Dev, Clin Biostat, Raritan, NJ USA
[4] Janssen Res & Dev, Clin Oncol, Spring House, PA USA
[5] Upstate Med Univ, Dept Urol, Syracuse, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期
关键词：
D O I：
10.1200/JCO.2022.40.6_suppl.TPS593
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS593
引用
收藏
页数：3
相关论文
共 17 条
  • [1] SunRISe-1: Phase IIb study of TAR-200 in combination with cetrelimab (CET), TAR-200 alone, or CET alone in participants with high risk non-muscle invasive bladder cancer unresponsive to intravesical bacillus Calmette-Guerin who are ineligible for or elected not to undergo radical cystectomy
    van der Heijden, M. S.
    Cutie, C.
    Acharya, M.
    Stromberg, K.
    Li, X.
    Beeharry, N.
    Stewart, R.
    Maffeo, J.
    Indoria, C.
    Levin, W.
    Jacob, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S723 - S724
  • [2] FIRST RESULTS FROM SUNRISE-1 IN PATIENTS WITH BCG UNRESPONSIVE HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER RECEIVING TAR-200 IN COMBINATION WITH CETRELIMAB, TAR-200, OR CETRELIMAB ALONE
    Daneshmand, Siamak
    van der Heijden, Michiel S.
    Jacob, Joseph M.
    Necchi, Andrea
    Xylinas, Evanguelos
    Morris, David S.
    Spiegelhalder, Philip
    Zainfeld, Daniel
    Kang, Taek Won
    Matulay, Justin T.
    Belkoff, Laurence H.
    Decaestecker, Karel
    Arentsen, Harm
    Hampras, Shalaka
    Jin, Shu
    Cutie, Christopher J.
    Sweiti, Hussein
    Stromberg, Katherine
    Martin, Jason
    Simone, Giuseppe
    JOURNAL OF UROLOGY, 2023, 209 : E1187 - E1187
  • [3] SunRISe-3: TAR-200 plus cetrelimab or TAR-200 versus intravesical Bacillus Calmette-Guerin in patients with BCG-naive high-risk non-muscle-invasive bladder cancer
    Catto, J. W. F.
    Necchi, A.
    Powles, T.
    Guerrero-Ramos, F.
    Simone, G.
    Shore, N.
    Salinas, J. S.
    Merseburger, A. S.
    Roumiguie, M.
    Hiroshi, K.
    Morris, D. M.
    Qiang, W.
    Korkes, F.
    Hasan, M.
    Jin, S.
    Maffeo, J.
    Hammond, C.
    Sweiti, H.
    Somer, R. S.
    Chang, S. S.
    EUROPEAN UROLOGY, 2024, 85 : S1505 - S1505
  • [4] SunRISe-3: TAR-200 plus cetrelimab (CET) or TAR-200 versus intravesical bacillus Calmette-Guerin (BCG) in patients (pts) with BCG-naive high-risk non-muscle-invasive bladder cancer (HR NMIBC)
    Necchi, A.
    Catto, J. W. F.
    Powles, T. B.
    Guerrero-Ramos, F.
    Simone, G.
    Shore, N. D.
    Salinas, J.
    Merseburger, A. S.
    Roumiguie, M.
    Kitamura, H.
    Morris, D.
    Wei, Q.
    Korkes, F.
    Hasan, M.
    Jin, S.
    Maffeo, J.
    Hammond, C.
    Sweiti, H.
    Somer, R.
    Chang, S. S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1224 - S1224
  • [5] SAFETY AND TOLERABILITY OF TAR-200 MONOTHERAPY IN PATIENTS WITH BACILLUS CALMETTE-GUERIN (BCG)UNRESPONSIVE HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER (HR NMIBC) IN SUNRISE-1
    Siamak, Daneshmand
    Daniel, Zainfeld
    Christopher, Pieczonka
    Giuseppe, Simone
    Michiel, S. van der Heijden
    Martin, Bogemann
    David, S. Morris
    Philipp, Spiegelhalder
    Laurence, H. Belkoff
    Karel, Decaestecker
    Harm, Arentsen
    Shalaka, Hampras
    Christopher, J. Cutie
    Hussein, Sweiti
    Katharine, Stromberg
    Jason, Martin
    Abhijit, Shukla
    Joseph, M. Jacob
    Evanguelos, Xylinas
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2025, 43 (03)
  • [6] Results from SunRISe-1 in patients with Bacillus Calmette-Guerin-unresponsive high-risk non-muscle-invasive bladder cancer receiving TAR-200 monotherapy
    Necchi, A.
    Jacob, J. M.
    Daneshmand, S.
    Simone, G.
    Xylinas, E.
    Morris, D. S.
    Spiegelhalder, P.
    Zainfeld, D.
    Kang, T. W.
    Matulay, J. T.
    Belkoff, L. H.
    Decaestecker, K.
    Arentsen, H.
    Hampras, S.
    Cutie, C. J.
    Sweiti, H.
    Stromberg, K.
    Martin, J.
    Shulka, A.
    Van Der Heijden, M. S.
    EUROPEAN UROLOGY, 2024, 85 : S1508 - S1509
  • [7] SunRISe-4: TAR-200 plus cetrelimab or cetrelimab alone as neoadjuvant therapy in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or refuse neoadjuvant platinum-based chemotherapy.
    Psutka, Sarah P.
    Cutie, Christopher
    Bhanvadia, Sumeet Kaur
    Keegan, Kirk A.
    Crist, Wendy
    Tian, Shaozhou Ken
    Maffeo, John
    Raybold, Bradley
    Kashmer, Marietta
    Hasan, Mohamad
    Li, Xiang
    Beeharry, Neil
    Thomas, Shibu
    Tian, Hui
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [8] TAR-200+/- cetrelimab (CET) and CET alone in patients (pts) with bacillus Calmette- Guerin-unresponsive (BCG UR) high-risk non-muscle-invasive bladder cancer (HR NMIBC): Updated results from SunRISe-1 (SR-1)
    van der Heijden, M. S.
    Simone, G.
    Boegemann, M.
    Xylinas, E.
    Roumiguie, M.
    Guerrero-Ramos, F.
    Necchi, A.
    Daneshmand, S.
    Van Praet, C.
    Spiegelhalder, P.
    Decaestecker, K.
    Arentsen, H.
    Zainfeld, D.
    Hampras, S.
    Cutie, C. J.
    Sweiti, H.
    Stromberg, K.
    Martin, J.
    Shukla, A.
    Jacob, J. M.
    ANNALS OF ONCOLOGY, 2024, 35 : 1272 - 1273
  • [9] SUNRISE-2: A PHASE 3, MULTICENTER, RANDOMIZED STUDY EVALUATING THE EFFICACY OF TAR-200 IN COMBINATION WITH CETRELIMAB VERSUS CONCURRENT CHEMORADIOTHERAPY IN PARTICIPANTS WITH MUSCLE-INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER
    Williams, Stephen
    Cutie, Christopher
    Keegan, Kirk
    Raybold, Bradley
    Stewart, Rachel
    Acharya, Milin
    Zhu, Wei
    Li, Xiang
    O'Dondi, Lang
    Beeharry, Neil
    Spratt, Daniel
    JOURNAL OF UROLOGY, 2021, 206 : E250 - E250
  • [10] SUNRISE-5: A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF TAR-200 COMPARED WITH INTRAVESICAL CHEMOTHERAPY AFTER BACILLUS CALMETTE-GUERIN IN RECURRENT HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER
    Sima, Porten
    Sumeet, Bhanvadia
    Saltanat, Najmi
    Hussein, Sweiti
    John, Maffeo
    Kate, Stromberg
    Jovita, Gale
    Benjamin, Pradere
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2025, 43 (03)
12